基于肿瘤学的体内CRO市场（按动物模型、给药途径、治疗方法和最终用户划分）－2025-2032年全球预测

预计到 2032 年，肿瘤体内 CRO 市场将成长至 34.3 亿美元，复合年增长率为 11.75%。

明确肿瘤领域体内研究的策略要务，以加速转化突破、降低研究失败率并加强相关人员的临床前决策。

癌症研究领域依然复杂多变，经营团队需要简洁明了、切实可行的洞察，才能做出直接影响后续临床结果的临床前决策。本执行摘要整合了营运、科学和策略观点，阐明了体内研究能力在哪些方面最为重要，实验设计选择如何影响转化应用，以及应指导服务和伙伴关係投资的组织优先事项。

免疫工程、精准模型、整合分析和协作生态系统驱动的不断发展的临床前范式正在重塑肿瘤体内研究实践。

临床前研究环境正在经历变革性变化，改变癌症计画的规划和实施方式。免疫工程的进步以及人源化和基因定义的动物模型的成熟，提高了实验机制的可重复性。同时，包括机器学习驱动的影像分析和生物标记纵向追踪在内的综合分析技术，正在将复杂的体内数据转化为清晰、可操作的指标。这些技术进步也正在推动组织变革。发现、转化和临床团队之间的紧密合作，使得临床相关终点能够更早达成共识。

评估新兴贸易壁垒对肿瘤领域体内测试服务提供和全球研究连续性营运成本、监管和创新的连锁影响

新的贸易政策和关税制度除了直接增加采购成本外，还会产生复杂的后续影响。对进口试剂、特殊动物品系和关键设备征收更高的关税，并加强海关审查，会导致采购时间延长、供应链分散以及库存维修成本增加。实际上，这些营运上的摩擦会直接导致研究启动延迟、实验週期缩短以及寻找替代供应来源的困难，从而降低癌症计画进度安排的可预测性。

分析模型选择、给药途径、治疗方法和最终用户细分，以揭示体内肿瘤学中细微的需求驱动因素及其对实验设计的影响。

清晰的细分观点能够明确科学和商业性优先事项的分歧所在，并指导如何根据实验目标优化资源分配。以动物模型划分，研究通常分为鼠类和非鼠类两类。鼠类模型包括基因工程小鼠模型、免疫功能健全的同基因小鼠模型和小鼠异种移植模型，而非鼠类模型则包含犬、兔子和大鼠模型。每类模型在免疫学、药理学和毒理学终点方面各有优势，这些优势直接指导研究设计决策和供应商选择。因此，专案经理必须使模型选择与作用机制和感兴趣的转化研究问题相符。

区域比较分析突显了世界各地肿瘤研究中心在策略重点、供应链实践、监管环境和合作机会方面的差异。

区域趋势影响着能力的建构方式、供应链的结构以及科学合作的活跃程度。在美洲，转化医学专长的集中、强大的生物技术生态系统以及完善的肿瘤免疫学基础设施，促进了高通量、以转化医学为导向的体内研究项目的发展，这些项目需要快速迭代并与临床研发管线紧密衔接。该地区的监管能力和活跃的创业投资活动支持申办方和服务供应商之间的灵活伙伴关係，同时也强调了可重复性和文件记录的重要性。

服务供应商之间的竞争定位和能力差异化可能会专注于专业动物模型、技术整合、资讯服务和策略联盟。

肿瘤领域体内试验的竞争格局日益凸显，其关键在于服务能力的广度、专业知识的深度以及将资讯服务与湿实验室操作相结合的能力。能够同时拥有先进的小鼠模型、检验的非小鼠毒理学平台以及严谨的给药途径专业知识的服务商，可以为转化医学计画提供差异化的端到端解决方案。同样重要的是，服务商还需具备满足特定治疗方式需求的能力，例如免疫查核点抑制剂的免疫治疗终点检测，以及激酶抑制剂和小分子药物的药物动力学和标靶结合检测。

为领导者提供切实可行的策略建议，以增强营运韧性、优先考虑科学投资并加速临床前肿瘤学计画的转化价值。

产业领导者应采取多管齐下的策略方法，在充分利用科学进步的同时，确保业务连续性。首先，应实现采购和库存策略多元化，以降低动物品系、特殊试剂和关键设备等单一故障点所带来的风险。建立检验的替代供应商并维持关键组件的滚动库存，有助于即使在外部贸易和物流中断的情况下也能维持测试计划的进行。其次，应优先投资于反映治疗重点领域的模型组合。例如，应保持基因工程小鼠模型、免疫功能健全的同基因移植系统和关键的非小鼠毒理学模型之间的平衡组合，以应对各种转化医学挑战。

结合关键相关人员的见解、实验室检验、营运审核和精心挑选的二手证据，采用稳健的三角测量方法，可确保得出严谨且可操作的结论。

本执行摘要的调查方法结合了定性一手调查、有针对性的营运检验以及精心挑选的二手证据，以确保研究结果严谨且具有直接适用性。关键投入包括对资深转换科学家、营运负责人和采购专家进行结构化访谈，以收集关于模型选择、供应商绩效和物流挑战的第一手资讯。此外，还辅以营运审核和实验室访问，以检验工作流程、模型培育计划和资料收集流程，从而对报告的能力进行实地验证。

明确总结营运洞察、科学趋势和战略意义，以指导业务决策并优化肿瘤学领域的近期研究计划。

这种整合凸显了临床前肿瘤学研究中的几个永恆真理：模型选择至关重要，运作韧性支撑着转化研究的可靠性，而整合的资料实践则缩短了从实验中观察到专案决策的流程。免疫肿瘤学和标靶治疗的科学进步需要与作用机制、给药途径和临床终点相匹配的专门体内策略。同时，从贸易措施到区域监管差异等外部压力，都要求申办方和提供者投资于采购多元化、建立在地化能力以及加强合约框架。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 扩展人源化小鼠模型，用于对需要复杂T细胞交互作用的免疫肿瘤疗法进行临床前评估。
• 整合先进的体内显微镜和PET/MRI成像技术，以增强体内模型中肿瘤进展和药物分布的即时研究
• 引入基于 CRISPR/Cas9 的肿瘤模型可加速肿瘤学领域体内研究的标靶检验和功能基因组学分析。
• 透过引入反映不同肿瘤异质性的患者来源异种移植模型（PDX），实现个人化癌症治疗测试策略
• 利用高性能体内筛检平台加速先导化合物，缩短新药临床试验申请（IND）提交时间
• 为满足日益增长的符合监管标准的肿瘤数据需求，亚太地区正在扩大符合GLP规范的体内CRO设施。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 基于动物模型的肿瘤体内CRO市场

• 老鼠
  • 基因工程小鼠模型
  • 免疫功能健全的同基因模型
  • 小鼠异种移植模型
• 非滑鼠
  • 狗
  • 兔子
  • 鼠

9. 依给药管道分類的肿瘤体内CRO市场

• 静脉
• 口服
• 皮下

10.治疗方法领域体内CRO市场

• 化疗
• 免疫疗法
  • 查核点抑制剂
  • 单株抗体
• 标靶治疗
  • 激酶抑制剂
  • 小分子抑制剂

11. 依最终用户分類的肿瘤体内CRO市场

• 学术和研究机构
• 合约研究组织
• 製药公司

12. 各地区肿瘤体内CRO市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

13. 肿瘤体内CRO市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

14. 各国肿瘤体内CRO市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Charles River Laboratories International, Inc.
  • Laboratory Corporation of America Holdings
  • WuXi AppTec Co., Ltd.
  • Inotiv, Inc.
  • Crown Bioscience, Inc.
  • Taconic Biosciences, Inc.
  • Pharmaron（Group）Co., Ltd.
  • Explora BioLabs, Inc.
  • GenScript ProBio Co., Ltd.
  • Oncodesign SA

The Oncology Based In-Vivo CRO Market is projected to grow by USD 3.43 billion at a CAGR of 11.75% by 2032.

Framing the strategic imperative for oncology in-vivo research to accelerate translational breakthroughs, reduce attrition, and strengthen preclinical decision-making across stakeholders

The landscape of oncology research remains complex and dynamic, and executives require concise, actionable intelligence to make preclinical decisions that directly influence downstream clinical outcomes. This executive summary synthesizes operational, scientific, and strategic perspectives to clarify where in-vivo capabilities matter most, how experimental design choices shape translational relevance, and which organizational priorities should guide investment in services and partnerships.

Throughout the report, emphasis is placed on the intersection between scientific rigor and operational resilience. Translational value depends not only on model selection and dosing paradigms but also on supply chain integrity, data fidelity, and regulatory alignment. Consequently, the executive view focuses on practical levers that reduce technical attrition, accelerate validation timelines, and improve reproducibility across multicenter programs. By concentrating on decision points that executives can influence-such as model portfolios, vendor qualification, and integrated data pipelines-this introduction sets the stage for a pragmatic, strategy-forward conversation that informs both near-term actions and medium-term capability building.

The intent is to equip decision-makers with a clear framework for aligning scientific priorities with commercial realities and operational constraints, thereby enabling more predictable and effective progression from preclinical insights to clinical hypotheses.

Evolving preclinical paradigms driven by immunoengineering, precision models, integrated analytics, and collaborative ecosystems that are reshaping oncology in-vivo research practices

The preclinical research environment has been undergoing transformative shifts that are changing how oncology programs are designed and executed. Advances in immunoengineering and the maturation of humanized and genetically defined animal models are improving the mechanistic fidelity of experiments. At the same time, integrated analytics, including machine learning-enabled image analysis and longitudinal biomarker tracking, are turning complex in-vivo datasets into clearer go/no-go signals. These technological evolutions are accompanied by organizational shifts: tighter collaboration between discovery, translational, and clinical teams is enabling earlier alignment on endpoints that matter clinically.

Concurrently, the industry is seeing methodological convergence between in-vivo and ex vivo approaches. Organoid systems and sophisticated co-culture platforms are increasingly used to triage candidates before committing to resource-intensive animal studies, thereby creating a cascade effect that raises the bar for the in-vivo experiments that are performed. Regulatory expectations and reproducibility imperatives are also prompting greater standardization of protocols and metadata capture, leading providers to invest in quality systems and data harmonization. Together, these shifts are not merely incremental; they are reshaping service offerings, partnership models, and the criteria by which translational success is judged.

Assessing the cascading operational, cost, regulatory, and innovation effects of emerging trade barriers on oncology in-vivo service delivery and global research continuity

Emerging trade policies and tariff regimes have introduced a complex set of downstream effects that extend beyond immediate procurement costs. Increased duties and customs scrutiny for imported reagents, specialized animal strains, and critical equipment can lead to longer lead times, fragmented supply chains, and higher inventory carrying costs. In practice, these operational frictions often translate into delayed study starts, compressed experiment windows, and the need for contingency sourcing, all of which erode schedule predictability for oncology programs.

Further, tariffs can alter vendor economics and sourcing decisions, prompting some providers to localize certain functions or to reconfigure service portfolios to rely less on imported components. This reconfiguration can have knock-on effects for model availability, especially for specialized or proprietary strains that are produced in geographically concentrated facilities. In turn, sponsors and service providers face a choice between maintaining tight biological fidelity through original model use or accepting alternative models that may introduce translational risk.

Importantly, the cumulative impact of trade measures also affects collaborative research that depends on cross-border sample transfers or multinational study coordination. To maintain momentum, research leaders must prioritize supply chain transparency, diversify vendor relationships, and incorporate contingency planning into project timelines. When combined with improved forecasting and contractual flexibility, such measures help mitigate the operational uncertainty introduced by evolving tariff environments.

Dissecting model selection, administration routes, therapeutic modalities, and end user segmentation to reveal nuanced demand drivers and experimental design implications for in-vivo oncology

A robust segmentation lens clarifies where scientific and commercial priorities diverge, and how resource allocation should be tailored to experimental intent. When examined by animal model, studies are commonly categorized into murine and non-murine groups; murine models include genetically engineered mouse models, immunocompetent syngeneic models, and mouse xenografts, while non-murine options encompass dog, rabbit, and rat models. Each of these model classes has different strengths for immunology, pharmacology, and toxicology endpoints, which directly guides study design decisions and vendor selection. Thus, portfolio managers should align model choice with the mechanism of action and the translational questions at hand.

Route of administration segmentation-typically intravenous, oral, and subcutaneous-further refines experimental planning. Dosing route influences pharmacokinetics, formulation strategies, and safety assessment, and therefore it must be considered early in preclinical development to ensure clinically relevant exposure. Therapeutic modality segmentation delineates distinct developmental pathways: chemotherapy, immunotherapy, and targeted therapy; within immunotherapy, checkpoint inhibitors and monoclonal antibodies are principal subcategories, and within targeted therapy, kinase inhibitors and small molecule inhibitors define technical approaches. These modality distinctions have operational implications for dosing regimens, biomarker selection, and model suitability.

Finally, end user segmentation-covering academia and research institutes, contract research organizations, and pharmaceutical companies-reveals differing expectations around throughput, documentation rigor, and customization. Academic customers often prioritize exploratory endpoints and method development, whereas pharmaceutical sponsors emphasize regulatory readiness and data traceability. Contract research organizations occupy an intermediary role, balancing standardization with bespoke services to serve both academic and industry clients. Together, these segmentation dimensions create a matrix that should inform capability investments, pricing strategies, and partnership models.

Comparative regional dynamics highlighting distinct strategic priorities, supply chain realities, regulatory landscapes, and collaborative opportunities across global oncology research hubs

Regional dynamics shape how capabilities are developed, how supply chains are structured, and where scientific collaboration is most active. In the Americas, there is a concentration of translational expertise, strong biotech ecosystems, and established infrastructure for immuno-oncology, which encourages high-throughput, translationally focused in-vivo programs that demand rapid iteration and close integration with clinical pipelines. This region's regulatory familiarity and dense venture capital activity support agile partnerships between sponsors and service providers, yet it also places a premium on reproducibility and documentation practices.

In Europe, Middle East & Africa, variations in regulatory frameworks and research funding models create heterogeneity in capability and demand. Institutional collaborations and multi-center academic networks often drive innovation here, and providers frequently need to accommodate a broader spectrum of compliance requirements and language-specific documentation. Supply chain considerations can vary significantly across countries, making regional logistics expertise and local inventory strategies important for maintaining timelines.

Asia-Pacific is characterized by fast-growing research capacity, increasing domestic pharmaceutical R&D, and a rising share of outsourced preclinical work. This region offers opportunities for cost-effective operations, access to diverse biological models, and expanding laboratory infrastructure. However, leaders must navigate differing regulatory expectations, local ethical standards, and the need for robust quality management systems to ensure data generated locally is acceptable to multinational sponsors. Altogether, regional distinctions influence how providers prioritize investments and how sponsors allocate studies to maximize both scientific validity and operational efficiency.

Competitive positioning and capability differentiation among service providers emphasizing specialized animal models, technology integration, data services, and strategic alliances

Competitive dynamics in the oncology in-vivo space are increasingly defined by capability breadth, specialization depth, and the ability to integrate data services with wet-lab operations. Providers that combine access to advanced murine models, validated non-murine toxicology platforms, and rigorous route-of-administration expertise can offer differentiated end-to-end solutions for translational programs. Equally important is the capacity to support modality-specific needs, such as immunotherapy endpoint assays for checkpoint inhibitors or pharmacokinetic and target engagement assays for kinase inhibitors and small molecule programs.

Beyond technical offerings, leading firms are investing in standardized reporting, electronic data capture, and analytics platforms that translate raw experimental outputs into decision-ready intelligence. Strategic alliances and co-development arrangements with discovery organizations are also shaping the competitive landscape, enabling providers to participate earlier in candidate selection and to influence preclinical strategy. Service differentiation is furthermore influenced by geographical reach and supply chain robustness; providers with localized breeding facilities, decentralized reagent sourcing, and clear export/import expertise are more resilient to operational shocks.

Intellectual property considerations and the emergence of specialized contract service verticals-such as immuno-oncology platforms or precision oncology models-create niches that smaller, highly specialized providers can exploit. For sponsors, selecting a partner increasingly involves assessing both technical fit and the provider's ability to adapt protocols, share data transparently, and align around development timelines.

Actionable strategic recommendations for leaders to build operational resilience, prioritize scientific investments, and accelerate translational value from preclinical oncology programs

Industry leaders should adopt a multi-pronged strategic approach to capitalize on scientific advances while safeguarding operational continuity. First, diversify sourcing and inventory strategies to reduce exposure to single-point failures in animal strains, specialized reagents, and critical equipment. Building validated alternative suppliers and maintaining rolling inventory for key components will preserve study schedules when external trade or logistics disruptions occur. Second, prioritize investment in model portfolios that reflect therapeutic focus areas; for example, retain a balanced mix of genetically engineered mouse models, immunocompetent syngeneic systems, and key non-murine toxicology models to cover a broad spectrum of translational questions.

Third, integrate data management and analytics capabilities with laboratory operations to ensure high-quality metadata capture, reproducible protocols, and rapid downstream analysis. Establishing common data standards across internal and external partners reduces ambiguity in interpretation and accelerates decision cycles. Fourth, engage proactively with regulatory and ethical bodies to harmonize expectations for study design, humane use of animals, and data transparency; early engagement mitigates rework and supports cross-border acceptability of data. Finally, invest in talent development and cross-functional teams that bridge discovery, translational science, and operations so that experimental design decisions are aligned with program objectives and commercial imperatives.

Taken together, these measures create a resilient, scientifically robust platform that supports faster, more reliable translation of preclinical findings into clinical investigation.

Robust triangulation approach combining primary stakeholder intelligence, laboratory validations, operational audits, and curated secondary evidence to ensure rigorous actionable conclusions

The research methodology underpinning this executive synthesis combines qualitative primary engagement, targeted operational validation, and curated secondary evidence to ensure findings are both rigorous and directly applicable. Primary inputs included structured interviews with senior translational scientists, operational leaders, and procurement specialists to capture first-hand perspectives on model selection, vendor performance, and logistics challenges. These interviews were complemented by operational audits and lab visits that validated workflows, model breeding programs, and data capture processes, providing on-the-ground confirmation of reported capabilities.

Secondary evidence was assembled from open literature, technical white papers, and regulatory guidance documents to contextualize technological trends and evolving best practices. To ensure reliability, findings were triangulated across multiple sources and checked for internal consistency; where divergent perspectives emerged, follow-up queries were used to reconcile differences and to clarify the operational implications. Quality control procedures included protocol traceability checks, verification of assay validation status, and assessment of data management practices to confirm reproducibility claims.

By combining stakeholder insight with empirical validation and documentary review, the methodology balances depth and breadth, resulting in conclusions that are both evidence-based and pragmatic for decision-makers.

Clear conclusions synthesizing operational insights, scientific trends, and strategic implications to guide executive decision-making and near term research program optimization in oncology

This synthesis brings into focus several enduring truths for preclinical oncology research: model choice matters, operational resilience underwrites translational confidence, and integrated data practices shorten the path from experimental observation to program decision. Scientific progress in immuno-oncology and targeted therapeutics demands tailored in-vivo strategies that reflect mechanism of action, dosing route, and clinical endpoints. At the same time, external pressures-ranging from trade measures to regional regulatory variation-require that sponsors and providers alike invest in diversified sourcing, localized capabilities, and stronger contractual frameworks.

Looking ahead, organizations that harmonize scientific rigor with operational discipline will be best positioned to de-risk early development and to deliver reproducible, clinically meaningful data. This requires a sustained focus on capability building, cross-functional alignment, and strategic partnerships that enable earlier access to translational expertise. Ultimately, the combination of advanced model systems, robust quality systems, and analytics that produce decision-ready outputs will determine which programs advance with confidence and which require further iteration.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of humanized mouse models for preclinical assessment of immuno-oncology therapies requiring complex T-cell interactions
• 5.2. Integration of advanced intravital microscopy and PET/MRI imaging to enhance real-time tumor progression and drug distribution studies in in-vivo models
• 5.3. Adoption of CRISPR/Cas9-engineered tumor models to accelerate target validation and functional genomics in oncology in-vivo research
• 5.4. Implementation of patient-derived xenograft (PDX) models reflecting diverse tumor heterogeneity for personalized oncology drug testing strategies
• 5.5. Utilization of high-throughput in-vivo screening platforms to expedite lead compound optimization and reduce time to IND submission
• 5.6. Expansion of GLP-compliant in-vivo CRO facilities in Asia-Pacific to meet the growing demand for regulatory-grade oncology data

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Based In-Vivo CRO Market, by Animal Model

• 8.1. Murine
  • 8.1.1. Genetically Engineered Mouse Model
  • 8.1.2. Immunocompetent Syngeneic
  • 8.1.3. Mouse Xenograft
• 8.2. Non Murine
  • 8.2.1. Dog
  • 8.2.2. Rabbit
  • 8.2.3. Rat

9. Oncology Based In-Vivo CRO Market, by Route Of Administration

• 9.1. Intravenous
• 9.2. Oral
• 9.3. Subcutaneous

10. Oncology Based In-Vivo CRO Market, by Therapeutic Modality

• 10.1. Chemotherapy
• 10.2. Immunotherapy
  • 10.2.1. Checkpoint Inhibitors
  • 10.2.2. Monoclonal Antibodies
• 10.3. Targeted Therapy
  • 10.3.1. Kinase Inhibitors
  • 10.3.2. Small Molecule Inhibitors

11. Oncology Based In-Vivo CRO Market, by End User

• 11.1. Academia & Research Institute
• 11.2. Contract Research Organization
• 11.3. Pharmaceutical

12. Oncology Based In-Vivo CRO Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Oncology Based In-Vivo CRO Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Oncology Based In-Vivo CRO Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Charles River Laboratories International, Inc.
  • 15.3.2. Laboratory Corporation of America Holdings
  • 15.3.3. WuXi AppTec Co., Ltd.
  • 15.3.4. Inotiv, Inc.
  • 15.3.5. Crown Bioscience, Inc.
  • 15.3.6. Taconic Biosciences, Inc.
  • 15.3.7. Pharmaron (Group) Co., Ltd.
  • 15.3.8. Explora BioLabs, Inc.
  • 15.3.9. GenScript ProBio Co., Ltd.
  • 15.3.10. Oncodesign SA

LIST OF FIGURES

• FIGURE 1. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ONCOLOGY BASED IN-VIVO CRO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 200. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 201. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
• TABLE 242. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
• TABLE 243. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
• TABLE 244. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
• TABLE 245. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
• TABLE 246. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
• TABLE 247. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 248. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 249. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
• TABLE 250. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 256. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 257. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
• TABLE 260. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
• TABLE 261. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
• TABLE 262. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
• TABLE 263. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
• TABLE 264. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
• TABLE 265. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 266. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 271. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 272. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 273. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 274. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 275. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
• TABLE 278. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
• TABLE 279. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
• TABLE 280. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
• TABLE 281. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2032 (USD MILLION)
• TABLE 287. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 288. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 289. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 290. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 291. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 292. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 293. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 294. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 295. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
• TABLE 298. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2032 (USD MILLION)
• TABLE 299. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
• TABLE 300. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2032 (USD MILLION)
• TABLE 301. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
• TABLE 302. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2032 (USD MILLION)
• TABLE 303. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 304. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 305. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY T